It has not been a great week so far for the Northwest Biotherapeutics (OTCMKTS:NWBO) stock, having corrected by 20% so far. However, investors need to note that since the middle of February, the stock is up by 15%.
The company came into focus last week after it announced that it submitted its application to the Medicines and Healthcare Products Regulatory Agency (MHRA) with regards to the certification of its Sawston facility in the United Kingdom. It is a significant development for Northwest and is the culmination of around two years of work.
In this regard, it is also necessary to point out that a major portion of the work completed by the company was done during the coronavirus pandemic. The preparations for the Sawston facility included a physical build-out and meticulous preparation of manufacturing records to be presented to the regulatory authorities. It is now going to be interesting to see if the stock can make a recovery over the coming days.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.